Euvichol-plus vaccine campaign coverage during the 2017/2018 cholera outbreak in Lusaka district, Zambia: a cross-sectional descriptive study.
epidemiologic studies
epidemiology
infectious diseases
public health
tropical medicine
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
05 10 2023
05 10 2023
Historique:
medline:
1
11
2023
pubmed:
6
10
2023
entrez:
5
10
2023
Statut:
epublish
Résumé
To determine the coverage for the oral cholera vaccine (OCV) campaign conducted during the 2017/2018 cholera outbreak in Lusaka, Zambia. A descriptive cross-sectional study employing survey method conducted among 1691 respondents from 369 households following the second round of the 2018 OCV campaign. Four primary healthcare facilities and their catchment areas in Lusaka city (Kanyama, Chawama, Chipata and Matero subdistricts). A total of 1691 respondents 12 months and older sampled from 369 households where the campaign was conducted. A satellite map-based sampling technique was used to randomly select households. A pretested electronic questionnaire uploaded on an electronic tablet (ODK V.1.12.2) was used for data collection. Descriptive statistics were computed to summarise respondents' characteristics and OCV coverage per dose. Bivariate analysis (χ The overall coverage for the first, second and two doses were 81.3% (95% CI 79.24% to 83.36%), 72.1% (95% CI 69.58% to 74.62%) and 66% (95% CI 63.22% to 68.78%), respectively. The drop-out rate was 18.8% (95% CI 14.51% to 23.09%). Of the 81.3% who received the first dose, 58.8% were female. Among those who received the second dose, the majority (61.0%) were females aged between 5 and 14 years (42.6%) and 15 and 35 years (27.7%). Only 15.5% of the participants aged between 36 and 65 and 2.5% among those aged above 65 years received the second dose. These findings confirm the 2018 OCV campaign coverage and highlight the need for follow-up surveys to validate administrative coverage estimates using population-based methods. Reliance on health facility data alone may mask low coverage and prevent measures to improve programming. Future public health interventions should consider sociodemographic factors in order to achieve optimal vaccine coverage.
Identifiants
pubmed: 37798024
pii: bmjopen-2022-070796
doi: 10.1136/bmjopen-2022-070796
pmc: PMC10565249
doi:
Substances chimiques
Cholera Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e070796Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Emerg Infect Dis. 2017 Jan;23(1):38-45
pubmed: 27983502
Lancet Infect Dis. 2017 Oct;17(10):1080-1088
pubmed: 28729167
BMJ Open. 2022 Nov 23;12(11):e058028
pubmed: 36418116
Vaccine. 2017 Oct 13;35(43):5819-5827
pubmed: 28916247
Vaccine. 2015 Nov 17;33(46):6360-5
pubmed: 26348402
BMJ Open. 2022 Nov 11;12(11):e066945
pubmed: 36368745
Vaccine. 2016 Dec 7;34(50):6112-6113
pubmed: 27899197
Vaccine. 2019 Oct 8;37(43):6348-6355
pubmed: 31521413
Ther Adv Vaccines. 2014 Sep;2(5):123-36
pubmed: 25177492
Bull World Health Organ. 2018 Feb 01;96(2):86-93
pubmed: 29403111
BMJ Open. 2020 Dec 10;10(12):e038464
pubmed: 33303438
CMAJ. 2015 Apr 21;187(7):E207-E208
pubmed: 25802313
PLoS One. 2018 Oct 3;13(10):e0198592
pubmed: 30281604
BMJ Open. 2022 Sep 7;12(9):e053585
pubmed: 36547726
Lancet Glob Health. 2018 Sep;6(9):e1028-e1035
pubmed: 30103980
PLoS One. 2014 Jul 01;9(7):e99381
pubmed: 24983989
Curr Top Microbiol Immunol. 2014;379:17-47
pubmed: 24710767
Vaccine. 2017 Sep 12;35(38):5194-5200
pubmed: 28803712
Lancet Glob Health. 2016 Apr;4(4):e223-4
pubmed: 27013303
BMJ Open. 2022 Apr 5;12(4):e057589
pubmed: 35383080
PLoS Negl Trop Dis. 2013 Oct 17;7(10):e2465
pubmed: 24147164
Trop Med Int Health. 2017 Jul;22(7):822-829
pubmed: 28449319
BMC Infect Dis. 2012 Nov 05;12:287
pubmed: 23126504
Vaccine. 2015 May 15;33(21):2463-9
pubmed: 25850019
Qual Health Res. 2018 Oct;28(12):1933-1943
pubmed: 30175656
J Clin Microbiol. 2011 Nov;49(11):3739-49
pubmed: 21880975
Vaccine. 2020 Feb 29;38 Suppl 1:A31-A40
pubmed: 31395455
Vaccine. 2018 Sep 5;36(37):5617-5624
pubmed: 30087047
Bull World Health Organ. 2016 Sep 01;94(9):667-674
pubmed: 27708472